To accurately identify prognostic biomarkers for severity and progression of COVID-19. The identification of prognostic biomarkers for the severity and progression of COVID-19 is crucial to predict the risks of death in patients with COVID-19 (hyperinflation and exacerbated fibrosis) and therefore to prioritise healthcare resources and select appropriate therapeutic treatments. Using previously generated transcriptional data, MAFB transcription factors/soluble PAF-dependent factors whose serum levels will be determined in both mild and severe patients have been selected to identify accurate prognostic biomarkers for the severity and progression of COVID-19.

Principal Investigators: Angel L. Corbí y Miguel A. Vega (CIB)      

We use cookies on this site to improve your user experience. More info. ACEPTAR

Aviso de cookies